🎉 M&A multiples are live!
Check it out!

AC Immune Valuation Multiples

Discover revenue and EBITDA valuation multiples for AC Immune and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

AC Immune Overview

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab,  ACI-35.030, Semorinemab, ACI-7104.056, and others.


Founded

2003

HQ

United States of America
Employees

161

Website

acimmune.com

Financials

LTM Revenue $34.9M

LTM EBITDA -$39.0M

EV

-$43.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

AC Immune Financials

AC Immune has a last 12-month revenue of $34.9M and a last 12-month EBITDA of -$39.0M.

In the most recent fiscal year, AC Immune achieved revenue of $27.3M and an EBITDA of -$48.6M.

AC Immune expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See AC Immune valuation multiples based on analyst estimates

AC Immune P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $14.8M $27.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$51.8M -$48.6M XXX XXX XXX
EBITDA Margin -350% -178% XXX XXX XXX
Net Profit -$70.8M -$54.2M XXX XXX XXX
Net Margin -478% -199% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

AC Immune Stock Performance

As of April 15, 2025, AC Immune's stock price is $2.

AC Immune has current market cap of $153M, and EV of -$43.5M.

See AC Immune trading valuation data

AC Immune Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$43.5M $153M XXX XXX XXX XXX $-0.61

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

AC Immune Valuation Multiples

As of April 15, 2025, AC Immune has market cap of $153M and EV of -$43.5M.

AC Immune's trades at -1.4x LTM EV/Revenue multiple, and 1.3x LTM EBITDA.

Analysts estimate AC Immune's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for AC Immune and 10K+ public comps

AC Immune Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$43.5M XXX XXX XXX
EV/Revenue -1.6x XXX XXX XXX
EV/EBITDA 0.9x XXX XXX XXX
P/E -3.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get AC Immune Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

AC Immune Valuation Multiples

AC Immune's NTM/LTM revenue growth is 10%

AC Immune's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Over next 12 months, AC Immune's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate AC Immune's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for AC Immune and other 10K+ public comps

AC Immune Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 85% XXX XXX XXX XXX
EBITDA Margin -178% XXX XXX XXX XXX
EBITDA Growth -6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -168% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 42% XXX XXX XXX XXX
R&D Expenses to Revenue 229% XXX XXX XXX XXX
Opex to Revenue 292% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

AC Immune Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

AC Immune M&A and Investment Activity

AC Immune acquired  XXX companies to date.

Last acquisition by AC Immune was  XXXXXXXX, XXXXX XXXXX XXXXXX . AC Immune acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by AC Immune

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About AC Immune

When was AC Immune founded? AC Immune was founded in 2003.
Where is AC Immune headquartered? AC Immune is headquartered in United States of America.
How many employees does AC Immune have? As of today, AC Immune has 161 employees.
Who is the CEO of AC Immune? AC Immune's CEO is Dr. Andrea Pfeifer, PhD.
Is AC Immune publicy listed? Yes, AC Immune is a public company listed on NAS.
What is the stock symbol of AC Immune? AC Immune trades under ACIU ticker.
When did AC Immune go public? AC Immune went public in 2016.
Who are competitors of AC Immune? Similar companies to AC Immune include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of AC Immune? AC Immune's current market cap is $153M
What is the current revenue of AC Immune? AC Immune's last 12-month revenue is $34.9M.
What is the current EBITDA of AC Immune? AC Immune's last 12-month EBITDA is -$39.0M.
What is the current EV/Revenue multiple of AC Immune? Current revenue multiple of AC Immune is -1.4x.
What is the current EV/EBITDA multiple of AC Immune? Current EBITDA multiple of AC Immune is 1.3x.
What is the current revenue growth of AC Immune? AC Immune revenue growth between 2023 and 2024 was 85%.
Is AC Immune profitable? Yes, AC Immune is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.